A look at the content that grabbed most reader interest over the past year.
Amgen said they will continue to spread out their efforts on two different commercial models: biologics and biosimilars.
Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.
Sizing up his company amid a dismal annual results presentation, AstraZeneca CEO Pascal Soriot told analysts and investors: "We have become a little bit complicated and in many ways out of this, a bit conservative."
GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013.
Sales of Bristol-Myers Squibb's Plavix plunged 96% in the third quarter over the same period last year, contributing mightily to an overall 30% drop in sales of the company's products for the quarter, to $3.7 billion.
Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, the company said in a third quarter results call.
Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.
The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze.
Abbott Labs reported strong second quarter sales that, though mitigated by an unfavorable exchange rate, cheered analysts and investors, with muscular growth in Humira sales a high point.
Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.
Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.
Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected.
Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30.
AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.
Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.
Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation.
Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.